



## OPEN ACCESS

EDITED AND REVIEWED BY  
Nahed Ismail,  
University of Illinois at Chicago,  
United States

\*CORRESPONDENCE  
Prasanna K. Santhekadur  
prasannakumars@jssuni.edu.in

## SPECIALTY SECTION

This article was submitted to  
Clinical Microbiology,  
a section of the journal  
Frontiers in Cellular and  
Infection Microbiology

RECEIVED 17 October 2022  
ACCEPTED 18 November 2022  
PUBLISHED 07 December 2022

## CITATION

Thirunavukkarasu S and  
Santhekadur PK (2022) Editorial:  
Congruities between cancer and  
infectious diseases: Lessons to be  
learned from these distinct yet  
analogous fields.  
*Front. Cell. Infect. Microbiol.*  
12:1072022.  
doi: 10.3389/fcimb.2022.1072022

## COPYRIGHT

© 2022 Thirunavukkarasu and  
Santhekadur. This is an open-access  
article distributed under the terms of  
the Creative Commons Attribution  
License (CC BY). The use, distribution  
or reproduction in other forums is  
permitted, provided the original  
author(s) and the copyright owner(s)  
are credited and that the original  
publication in this journal is cited, in  
accordance with accepted academic  
practice. No use, distribution or  
reproduction is permitted which does  
not comply with these terms.

# Editorial: Congruities between cancer and infectious diseases: Lessons to be learned from these distinct yet analogous fields

Shyamala Thirunavukkarasu<sup>1</sup> and Prasanna K. Santhekadur<sup>2\*</sup>

<sup>1</sup>Department of Molecular Microbiology, Washington University in St. Louis School of Medicine, St. Louis, MO, United States, <sup>2</sup>Department of Biochemistry, Center of Excellence in Molecular Biology & Regenerative Medicine, Jagadguru Sri Shivarathreeshwara (JSS) Medical College, JSS Academy of Higher Education and Research, Mysore, Karnataka, India

## KEYWORDS

cancer, infectious diseases, bacteria, viruses, inflammation

## Editorial on the Research Topic

Congruities between cancer and infectious diseases: Lessons to be learned from these distinct yet analogous fields

It is a very well-established fact that cancer is a multifactorial disease involving innumerable complex cellular signaling pathways (Wu et al., 2018). These pathways are mainly regulated by oncogenes and tumor suppressor genes (Lee and Muller, 2010). Recent studies show that microRNAs (miRNAs) and associated RNA-induced silencing complex (RISC) also play a major role in oncogenesis (Yoo et al., 2011; Santhekadur and Kumar, 2019; Santhekadur et al., 2012). Infectious diseases are serious health disorders, and they are mainly caused by various unicellular or multicellular organisms such as bacteria, viruses, and fungi (Prasad et al., 2022; José et al., 2020). Infectious human viruses like human papillomavirus (HPV) cause cervical cancer; Epstein–Barr virus (EBV) is known to cause nasopharyngeal cancer and Burkitt lymphoma. Liver-associated human viruses like hepatitis B virus (HBV) and hepatitis C virus (HCV) cause hepatitis and induce hepatocellular carcinoma (Liao, 2006). Bacteria, namely, *Helicobacter pylori*, are also known to cause gastric cancer (Prasad et al., 2022). Some of the fungal secondary metabolites and toxic chemicals are known to trigger mutations and initiate cancer growth and development (Ekwomadu et al., 2022). Fungal origin environmental toxins like aflatoxin and ochratoxin are known carcinogens and activate inflammation and carcinogenesis (Shiragannavar et al., 2021; Vamadevaiah and Santhekadur, 2022) (Felizardo and Câmara, 2013). Inflammation is a major contributor and a well-known hallmark of almost all of the infectious diseases and carcinogenesis. Inflammatory cytokines like tumor necrosis factor alpha (TNF- $\alpha$ ) and transcription factor nuclear factor kappa B (NF- $\kappa$ B) act as master regulators of inflammation-associated infectious

diseases and cancer (Santhekadur et al., 2012; Prasad et al., 2022). Therefore, although distinct, there exists a strong congruity between cancer and infectious diseases. This special collection of original research and review articles gave us new insights on the microorganism-associated cancer development and progression and also beneficial effects of fungal secondary metabolites in cancer therapeutics.

This Research Topic contains a study by Li et al. which showed that the reactivation of cytomegalovirus (CMV) or EBV is closely related to poor hematopoietic stem cell transplantation (HSCT) outcomes. CMV is strongly correlated with different types of cancer initiation, including breast, colon, prostate, and ovarian cancer. EBV infection also increases a person's susceptibility to certain types of cancer such as nasopharyngeal cancer, Burkitt lymphoma, and Hodgkin lymphoma. This retrospective study strongly interprets the dangerous effects of these two viruses even in patients who have undergone HSCT.

The ubiquitin proteasome pathways are involved in protein degradation and recycling; they also aid in amino acid homeostasis (Uriarte et al., 2021). The review article by Ignatz-Hoover et al. revealed that the proteasome acts as a highly promising appropriate therapeutic target to combat infectious diseases and different types of cancers. Dolatabadi et al. showed the presence of intracellular highly adherent-invasive *Escherichia coli* among different stages of the disease, family background, and history in treated colorectal cancer patients in Iran. Although *E. coli* is a harmless bacterium and is an important part of a healthy human gut microbiota, this study clearly shows the pathogenic nature of a few strains of *E. coli* in infectious diseases and cancers. A study by Varli et al. showed that acetonic extract and secondary metabolites from endolichenic fungus (*Nemania* sp. EL006872) exhibited immune checkpoint inhibitory activity especially in lung cancer cells. This study also shows the potential importance of fungal secondary metabolites, and they can be used as promising therapeutic molecules in cancer therapy. This article indirectly shows that these microbial metabolites not only cause inflammation and cancer but also carry importance in cancer

immunotherapy. Another study by Wang et al. also showed how fucoxanthin prevents breast cancer growth and metastasis by stopping circulating tumor cell adhesion and transendothelial migration. This study clearly shows the anticancer potential of fucoxanthin in which it inhibited the most important hallmarks of breast cancer by suppressing circulating tumor cell adhesion and transendothelial migration. Interestingly, this fucoxanthin is a xanthophyll carotenoid most abundantly present in microorganisms like macroalgae and multicellular organisms like brown seaweeds.

All of these elegant studies clearly show the existence of congruities between cancer and infectious diseases. Furthermore, additional experimental evidence and studies give more knowledge to understand these distinct yet analogous fields.

## Author contributions

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

## Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

## References

- Ekwomadu, T., Mwanza, M., and Musekiwa, A. (2022). Mycotoxin-linked mutations and cancer risk: A global health issue. *Int. J. Environ. Res. Public Health* 19 (13), 7754. doi: 10.3390/ijerph19137754
- Felizardo, R. J., and Câmara, N. O. (2013). Hepatocellular carcinoma, and food contamination: aflatoxins and ochratoxin a as a great prompter. *World J. Gastroenterol.* 19 (24), 3723–3725. doi: 10.3748/wjg.v19.i24.3723
- José, R. J., Periselneris, J. N., and Brown, J. S. (2020). Opportunistic bacterial, viral and fungal infections of the lung. *Med. (Abingdon)*. 48 (6), 366–372. doi: 10.1016/j.mpmed.2020.03.006
- Lee, E. Y., and Muller, W. J. (2010). Oncogenes and tumor suppressor genes. *Cold Spring Harb. Perspect. Biol.* 2 (10), a003236. doi: 10.1101/cshperspect.a003236
- Liao, J. B. (2006). Viruses and human cancer. *Yale J. Biol. Med.* 79 (3-4), 115–122. doi: 10.1016/j.yjbm.2019.09.009
- Prasad, S. K., Bhat, S., Shashank, D., C, R. A., R, S., Rachtanapun, P., et al. (2022). Bacteria-mediated oncogenesis and the underlying molecular intricacies: What we know so far. *Front. Oncol.* 12, 836004. doi: 10.3389/fonc.2022.836004
- Santhekadur, P. K., Das, S. K., Gredler, R., Chen, D., Srivastava, J., Robertson, C., et al. (2012). Multifunction protein staphylococcal nuclease domain containing 1 (SND1) promotes tumor angiogenesis in human hepatocellular carcinoma through novel pathway that involves nuclear factor κB and miR-221. *J. Biol. Chem.* 287 (17), 13952–13958. doi: 10.1074/jbc.M111.321646
- Santhekadur, P. K., and Kumar, D. P. (2019). RISC assembly and post-transcriptional gene regulation in hepatocellular carcinoma. *Genes Dis.* 7 (2), 199–204. doi: 10.1016/j.gendis.2019.09.009
- Shiragannavar, V. D., Gowda, N. G. S., Kumar, D. P., Mirshahi, F., and Santhekadur, P. K. (2021). Withaferin a acts as a novel regulator of liver X receptor-α in HCC. *Front. Oncol.* 10, 628506. doi: 10.3389/fonc.2020.628506

- Uriarte, M., Sen Nkwe, N., Tremblay, R., Ahmed, O., Messmer, C., Mashtalir, N., et al. (2021). Starvation-induced proteasome assemblies in the nucleus link amino acid supply to apoptosis. *Nat. Commun.* 12 (1), 6984. doi: 10.1038/s41467-021-27306-4
- Vamadevaiah, R. M., and Santhekadur, P. K. (2022). Herbal immunity booster-associated liver injury during COVID-19 pandemic and aflatoxins. *J. Clin. Exp. Hepatol.* 12 (1), 252–253. doi: 10.1016/j.jceh.2021.08.021
- Wu, S., Zhu, W., Thompson, P., and Hannun, Y. A. (2018). Evaluating intrinsic and non-intrinsic cancer risk factors. *Nat. Commun.* 9 (1), 3490. doi: 10.1038/s41467-018-05467-z
- Yoo, B. K., Santhekadur, P. K., Gredler, R., Chen, D., Emdad, L., Bhutia, S., et al. (2011). Increased RNA-induced silencing complex (RISC) activity contributes to hepatocellular carcinoma. *Hepatology* 53 (5), 1538–1548. doi: 10.1002/hep.24216